BMY — Bristol-Myers Squibb Company

Summary of Bristol-Myers Squibb (BMY) Q4 2025 Earnings Call

1. Key Financial Results and Metrics:

• Q4 Revenue: Approximately $12.5 billion, flat year-over-year.
• Growth Portfolio: Grew 15% to $7.4 billion, accounting for nearly 60% of total revenue.
• Full-Year Revenue: Growth portfolio increased 17% despite a $4 billion decline in the legacy portfolio.
• Earnings Per Share: Q4 diluted EPS was $1.26; full-year diluted EPS was $6.15.
• Gross Margin: Declined 210 basis points to 71.9% in Q4.
• Operating Expenses: Decreased by $1.2 billion from 2024 to $16.6 billion for the full year.
• Cash Position: Approximately $11 billion in cash equivalents and marketable securities.

2. Strategic Updates and Business Highlights:

• Product Performance:
  • Eliquis: Revenue increased 6% to nearly $3.5 billion in Q4.
  • Reblozyl: Grew 21%, annualizing over $2 billion.
  • Breyanzi: Saw a 47% increase in revenue, now approved for five cancer types.
  • Camzyos: Grew 57% to $353 million.
• Pipeline Developments:
  • Breyanzi received FDA approval for a new indication.
  • Multiple pivotal studies expected to report data in 2026, including for products like Nilvexin and iberdomide.
• Cost Savings Initiatives: Achieved $1 billion in savings in 2025, with plans for an additional $1 billion in 2026 and 2027.

3. Forward Guidance and Outlook:

• 2026 Revenue Guidance: Expected to be between $46 billion and $47.5 billion.
• Earnings Per Share Guidance: Projected adjusted diluted EPS between $6.05 and $6.35.
• Legacy Portfolio Decline: Anticipated decline of 12-16% due to ongoing loss of exclusivity (LOE) impacts.
• Eliquis Growth: Expected to grow 10-15% in 2026, but projected to decline by $1.5 to $2 billion in 2027 due to generic competition.

4. Bad News, Challenges, or Points of Concern:

• Legacy Portfolio Decline: Significant revenue loss from legacy products, particularly as LOE impacts continue.
• Generic Competition: Anticipated entry of generics for Eliquis and Orencia, leading to substantial revenue declines.
• Gross Margin Pressure: Continued decline in gross margins due to product mix and increased generic volumes.
• Market Dynamics: Competitive pressures in oncology and other therapeutic areas could impact growth.

5. Notable Q&A Insights:

• Eliquis Dynamics: Management emphasized the importance of pricing strategy adjustments and anticipated market share growth, despite the looming generic competition.
• Business Development Focus: The company aims to deepen its presence in existing therapeutic areas rather than pursuing new markets, although it remains open to compelling opportunities.
• Pipeline Confidence: Executives expressed optimism about upcoming pivotal data readouts and the potential for new products to enhance growth.
• CoBinfy and Competitive Landscape: Management acknowledged competitive pressures but highlighted CoBinfy's strong uptake and market access.
• Milvexian Study: Ongoing studies are expected to provide insights into its efficacy and safety profile, with potential implications for broader payer coverage.

Overall, Bristol-Myers Squibb demonstrated strong execution in 2025, with a focus on growth and pipeline advancements, while navigating challenges related to its legacy portfolio and impending generic competition.